| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1005250112 |
| P356 | DOI | 10.1186/AR2298 |
| P8608 | Fatcat ID | release_sfeuc2lydndnrpnq2jvyrsjpny |
| P932 | PMC publication ID | 2212584 |
| P698 | PubMed publication ID | 17892600 |
| P5875 | ResearchGate publication ID | 5951288 |
| P2093 | author name string | Kazuhiro Aoki | |
| Nobuyuki Miyasaka | |||
| Toshihiro Nanki | |||
| Kazuo Umezawa | |||
| Tetsuo Kubota | |||
| Keiichi Ohya | |||
| Yukiko Komano | |||
| Machiko Hoshino | |||
| P2860 | cites work | Effect of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cells | Q24812982 |
| The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 | ||
| Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis | Q28141482 | ||
| Bone resorption by osteoclasts | Q28145169 | ||
| Osteoclast differentiation and activation | Q29547556 | ||
| Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group | Q29616063 | ||
| Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts | Q29618116 | ||
| Minireview: the OPG/RANKL/RANK system | Q34102256 | ||
| A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss | Q34567407 | ||
| Osteoclasts are essential for TNF-alpha-mediated joint destruction | Q34826003 | ||
| Requirement for NF-kappaB in osteoclast and B-cell development | Q35199657 | ||
| Identification of a human peripheral blood monocyte subset that differentiates into osteoclasts | Q35605683 | ||
| Mechanistic insight into osteoclast differentiation in osteoimmunology | Q36073894 | ||
| Cytokines regulating osteoclast formation and function | Q36501069 | ||
| RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation | Q38307924 | ||
| Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand | Q38515705 | ||
| Autoamplification of NFATc1 expression determines its essential role in bone homeostasis | Q42972503 | ||
| TAT fusion proteins containing tyrosine 42-deleted IkappaBalpha arrest osteoclastogenesis | Q43641805 | ||
| Inhibition of tumor necrosis factor-alpha -induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin | Q43976225 | ||
| NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis | Q44049672 | ||
| Novel nuclear factor kappa B activation inhibitor prevents inflammatory injury in unilateral ureteral obstruction | Q44357448 | ||
| NFkappaB decoy oligodeoxynucleotides ameliorates osteoporosis through inhibition of activation and differentiation of osteoclasts | Q45856471 | ||
| Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1. | Q46375837 | ||
| Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo | Q47446256 | ||
| Osteoprotegerin deficiency and juvenile Paget's disease | Q48292818 | ||
| Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. | Q50779374 | ||
| Rapid preparation of fresh frozen tissue-engineered bone sections for histological, histomorphological and histochemical analyses. | Q51101797 | ||
| Chemokines regulate IL-6 and IL-8 production by fibroblast-like synoviocytes from patients with rheumatoid arthritis | Q74844694 | ||
| A selective NFkappaB inhibitor, DHMEQ, reduced atherosclerosis in ApoE-deficient mice | Q79456479 | ||
| 15-deoxy-Delta12,14-prostaglandin J2 negatively regulates rankl gene expression in activated T lymphocytes: role of NF-kappaB and early growth response transcription factors | Q79984740 | ||
| Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with early rheumatoid arthritis | Q80038515 | ||
| Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial | Q82690898 | ||
| The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction | Q83880460 | ||
| P433 | issue | 5 | |
| P921 | main subject | macrophage | Q184204 |
| P304 | page(s) | R97 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | Arthritis Research and Therapy | Q15757229 |
| P1476 | title | NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor | |
| P478 | volume | 9 |
| Q59100894 | Amelioration of severe TNBS induced colitis by novel AP-1 and NF- κ B inhibitors in rats |
| Q37855820 | Direct Rel/NF-κB inhibitors: structural basis for mechanism of action |
| Q36244303 | Excavatolide B Attenuates Rheumatoid Arthritis through the Inhibition of Osteoclastogenesis |
| Q92662248 | Fucoidan Prevents RANKL-Stimulated Osteoclastogenesis and LPS-Induced Inflammatory Bone Loss via Regulation of Akt/GSK3β/PTEN/NFATc1 Signaling Pathway and Calcineurin Activity |
| Q37080218 | GRIM19 ameliorates acute graft-versus-host disease (GVHD) by modulating Th17 and Treg cell balance through down-regulation of STAT3 and NF-AT activation |
| Q44182155 | Inhibition of the NF-κB pathway as a candidate therapeutic strategy for cryopyrin-associated periodic syndrome |
| Q37293337 | NF-kappaB signaling pathway and its therapeutic implications in human diseases |
| Q37449635 | NF-κB signaling and bone resorption |
| Q35085107 | TLR2-dependent modulation of osteoclastogenesis by Porphyromonas gingivalis through differential induction of NFATc1 and NF-kappaB. |
| Q37293344 | Targeting NF-kappaB: a promising molecular therapy in inflammatory arthritis. |
| Q37476144 | The NF-κB specific inhibitor DHMEQ prevents thrombus formation in a mouse model of antiphospholipid syndrome |
Search more.